How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,770 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Current evidence does not support the use of a negative D-dimer to rule out suspected pulmonary embolism in pregnancy.

patients. Search Strategy Medline 1950–23rd November 2010) and Embase (1980–2nd November 2010) via NHS Evidence (http://www.library.nhs.uk/). The Cochrane Library, 23rd November 2010. MEDLINE and EMBASE: (exp pulmonary embolism/OR exp venous thromboembolism/OR venous thromboembolism.mp. OR pulmonary embolism.mp.) AND (exp pregnant women/OR exp pregnancy/OR pregnant.mp. OR pregnancy.mp.) AND (exp fibrin fibrinogen degradation products/OR exp cross-linking reagents/OR D-dimer.mp. OR cross linking (...) , Netherlands Four studies eligible for inclusion, assessing diagnostic methods in pregnant patients with clinical suspicion of DVT/PE. Systematic review of diagnostic technique Studies utilising D-dimer estimation as a diagnostic test None Low number and poor quality of studies. No prospective studies on investigative strategies identified for PTE in pregnancy. Strict predefined inclusion criteria caused rejection of >2/3 potentially eligible papers. Venous thromboembolic event rates at 20 months

2011 BestBETS

162. Relationship between ABO blood group and pregnancy complications: a systematic literature analysis (PubMed)

diseases, including cardiovascular, infectious and neoplastic disorders, is now acknowledged. However, there is controversial information on the potential association between ABO blood type and adverse pregnancy outcomes, including pre-eclampsia and related disorders (eclampsia, HELLP syndrome and intrauterine growth restriction), venous thromboembolism, post-partum haemorrhage and gestational diabetes. To elucidate the role of ABO antigens in pregnancy-related complications, we performed a systematic (...) Relationship between ABO blood group and pregnancy complications: a systematic literature analysis Given the expression of ABO blood group antigens on the surface of a wide range of human cells and tissues, the putative interplay of the ABO system in human biology outside the area of transfusion and transplantation medicine constitutes an intriguing byway of research. Thanks to evidence accumulated over more than 50 years, the involvement of the ABO system in the pathogenesis of several human

Full Text available with Trip Pro

2016 Blood Transfusion

163. Study of the Platelet Function During the Last Month of Pregnancy

, Toulouse Study Details Study Description Go to Brief Summary: The objective is to compare women's platelet answer in the last month of pregnancy to women old enough to procreate, no pregnancy and without hormonal treatment. The hypothesis of research is that the decrease of platelet answer in pregnant women could not only limit the occurence of embolic accidents but also explain the lowest incidence of the arterial thrombosis in comparison with the venous thrombosis. Condition or disease Intervention (...) , antidepressants) Personal history of thromboembolic accident venous or arterial, Personal history of haemostasis disease Personal history of hepatic or renal disease Personal history of autoimmune disease. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2016 Clinical Trials

164. Validation of Ultrasound in Predicting a Low Lying Placenta Throughout Pregnancy

: On admission for delivery of the infant and postpartum day 1 and 2 ] To assess if the increased risk of venous thromboembolism is observed in obese versus non-obese pregnant patients is due to compromised flow in the lower extremities. Secondary Outcome Measures : Establishment of venous hemodynamics by venous duplex in obese pregnancy at the time of admission for delivery [ Time Frame: On admission for delivery of the infant and postpartum day 1 and 2 ] To establish a basis for venous hemodynamics (...) Validation of Ultrasound in Predicting a Low Lying Placenta Throughout Pregnancy Validation of Ultrasound in Predicting a Low Lying Placenta Throughout Pregnancy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2016 Clinical Trials

165. Electronic-personalized Program for Obesity in Pregnancy to Improve Delivery

outcome including instrumental delivery and Caesarean section, as clinically relevant outcomes because the mode of delivery is one of the major goals of the obstetrical management and is is strongly associated with body mass index and gestational weight gain. Condition or disease Intervention/treatment Phase Obesity Pregnancy Behavioral: ePPOP-ID program Not Applicable Detailed Description: Our study is an open, multicenter, randomized, parallel-group, controlled trial. This study will include obese (...) : No Criteria Inclusion Criteria: Obese pregnant women (30 ≤ BMI < 40 kg/m2) Singleton pregnancy between 12+0 to 19+6 weeks of pregnancy Having an email address and an Internet access Exclusion Criteria: BMI < 30 kg/m2 or BMI > 40 kg/m2 History of more than 2 miscarriages Severe heart disease (arrhythmias, history of myocardial infarction) Multiple pregnancy Unstable thyroid disease Uncontrolled hypertension Pre-gestational diabetes Bariatric surgery Any medical condition that may interfere with physical

2016 Clinical Trials

166. Study to Evaluate the Safety of Repatha® in Pregnancy

by (Responsible Party): Amgen Study Details Study Description Go to Brief Summary: To evaluate outcomes of pregnancy in females diagnosed with familial hypercholesterolaemia (FH), exposed to Repatha® during pregnancy. This includes follow-up of their infants to the age of 12 months Condition or disease Hypercholesterolaemia Pregnancy Detailed Description: Women diagnosed with familial hypercholesterolaemia (FH), treated at centres in Europe, South Africa and Australia, with pregnancy confirmed during (...) for additional information Studies a U.S. FDA-regulated Device Product: No Keywords provided by Amgen: hypercholesterolaemia Lipid lowering therapies Pregnancy Additional relevant MeSH terms: Layout table for MeSH terms Hypercholesterolemia Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Evolocumab Antibodies, Monoclonal Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Immunologic Factors

2016 Clinical Trials

167. Pulmonary Embolism in Pregnancy

Pulmonary Embolism in Pregnancy Pulmonary Embolism in Pregnancy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pulmonary Embolism (...) in Pregnancy Pulmonary Embolism in Pregnancy Aka: Pulmonary Embolism in Pregnancy II. Epidemiology See Two thirds of thromboembolic events in pregnancy are DVT (diagnosable by ) Overall risk of Pulmonary Embolism in Pregnancy: 3 in 10,000 Risk of increases with advancing pregnancy and especially postpartum First trimester : 1 in 50,000 Third trimester : 1 in 10,000 Two thirds of pregnancy-related occur postpartum (esp after ) III. Symptoms and signs See may be present Unilateral leg signs of may be present

2018 FP Notebook

168. Haematological malignancies in pregnancy: An overview with an emphasis on thrombotic risks. (PubMed)

-pregnant women of reproductive age. Reproductive organ involvement is observed in almost half of pregnant women with NHL. The association of acute leukaemia and pregnancy is infrequent and it is assumed that pregnancy does not accelerate the disease course. Both cancer and pregnancy induce a procoagulant state which can lead to maternal venous thromboembolism (VTE) and placental occlusion. Pregnancy in woman with myeloproliferative neoplasms (MPN) promotes thrombotic environment, associating (...) Haematological malignancies in pregnancy: An overview with an emphasis on thrombotic risks. With increase of maternal age, the incidence of haematological malignancies during pregnancy is rising and posing diagnostic and treatment challenges. Lymphoma is the fourth most common malignancy diagnosed in pregnancy; Hodgkin lymphoma is more frequent in pregnant women than non-Hodgkin lymphoma (NHL). The proportion of highly aggressive lymphomas in pregnant women is significantly higher than in non

2016 Thrombosis and haemostasis

169. Pregnancy After Cardiac Surgery (PubMed)

Pregnancy After Cardiac Surgery Heart disease is one of the common, indirect obstetric causes of maternal death. Management of these cases may challenge the entire team providing care to the mother and fetus. Advances in cardiac surgery has improved quality of life and level of functioning of cardiovascular system of patients with congenital or acquired heart disease. These diseases complicate 0.1-4 % pregnancies. Maternal complications in the form of thromboembolic, hemorrhagic episode (...) and heart failure may occur. The fetus is in danger of effects of oral anticoagulation therapy and other medications given to the patient in order to support cardiovascular system, intrauterine growth restriction and danger of hypoxia. In recent era, we are facing more pregnant patients with previous history of surgical correction of congenital or rheumatic heart disease. In this review, we have attempted to draw a management protocol of such patients based on the available literature and various

Full Text available with Trip Pro

2016 Journal of obstetrics and gynaecology of India

170. Recurrent Miscarriage, Antiphospholipid Antibodies and the Risk of Thromboembolic Disease. (PubMed)

Recurrent Miscarriage, Antiphospholipid Antibodies and the Risk of Thromboembolic Disease. Miscarriage affects 15 % of women, and while most are sporadic, there is a subset comprising 2-5 % of couples that suffers recurrent miscarriage (RM). Much work has been carried out to try to identify the RM underlying mechanisms. A subgroup of women with RM has been demonstrated to be in a prothrombotic state before pregnancy. The long-term health implications of this hypercoagulability may imply (...) an increased risk of thrombotic events, including ischemic heart disease. Moreover, the presence of antiphospholipid antibodies (aPL), rather than thrombophilic genetic defects (i.e., factor V Leiden or prothrombin G202010A mutation) in patients with RM, is a determinant of thrombotic events later in life, especially among those patients having also classic cardiovascular risk factors. These facts may have therapeutic implications. The efficacy of long-term thromboprophylaxis and its associated risk

2012 Clinical Reviews in Allergy & Immunology

171. Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension

Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension (RACE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2015 Clinical Trials

172. Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

are randomised to receive either Rivaroxaban or the standard treatment with low-molecular heparin. Condition or disease Intervention/treatment Phase Venous Thromboembolism Cancer Drug: Rivaroxaban Drug: low-molecular heparine Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 450 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title (...) thrombocytopenia II pregnant or breast-feeding women. Women of child-bearing potential must have a negative pregnancy test performed < 7 days prior to start of the treatment severe renal insufficiency (GFR < 30 ml/min) liver disease with coagulation impairment, including Child B and C cirrhosis acute medical illness treatment of the underlying cancer with experimental therapies Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2015 Clinical Trials

173. Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism. ADAM-VTE Condition or disease Intervention/treatment Phase Cerebral Vein Thrombosis Deep Vein Thrombosis (...) Embolism Venous Thromboembolism Pulmonary Embolism Venous Thrombosis Neoplasms, Second Primary Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Apixaban Dalteparin Heparin, Low-Molecular-Weight Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents

2015 Clinical Trials

174. Computed Tomography CT Venography During Postpartum Venous Thromboembolism

embolism (PE) results in a gain in venous thromboembolism detection rate. Condition or disease Intervention/treatment Phase Pulmonary Thromboembolism Procedure: computed tomography venography Not Applicable Detailed Description: Pulmonary embolism (PE) remains a leading cause of maternal death during postpartum in developed countries; Thoracic computed tomography angiography (CTA) is the first-line diagnostic test for PE suspicion, but has a 20 to 35% rate of inconclusiveness during pregnancy (...) Statement: Plan to Share IPD: No Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Pulmonary Embolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Embolism

2015 Clinical Trials

175. Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients

enoxaparin dosing strategies. Condition or disease Intervention/treatment Phase Traumatic Injury Venous Thromboembolism Drug: Enoxaparin 40 mg q12h Drug: Enoxaparin 30 mg q8h Phase 4 Detailed Description: This is a pilot study to determine if AT-III serum concentrations differ between patients with normal (>= 0.1 IU/mL) versus subtherapeutic (<0.1 IU/mL) anti-Xa trough concentrations when placed on enoxaparin 30 mg twice daily for venous thromboembolism (VTE) prophylaxis. Secondarily, this study (...) table for MeSH terms Thromboembolism Venous Thromboembolism Wounds and Injuries Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Heparin, Low-Molecular-Weight Dalteparin Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action

2015 Clinical Trials

176. Epidemiology of venous thromboembolism. (PubMed)

Epidemiology of venous thromboembolism. Thrombosis can affect any venous circulation. Venous thromboembolism (VTE) includes deep-vein thrombosis of the leg or pelvis, and its complication, pulmonary embolism. VTE is a fairly common disease, particularly in older age, and is associated with reduced survival, substantial health-care costs, and a high rate of recurrence. VTE is a complex (multifactorial) disease, involving interactions between acquired or inherited predispositions to thrombosis (...) and various risk factors. Major risk factors for incident VTE include hospitalization for surgery or acute illness, active cancer, neurological disease with leg paresis, nursing-home confinement, trauma or fracture, superficial vein thrombosis, and-in women-pregnancy and puerperium, oral contraception, and hormone therapy. Although independent risk factors for incident VTE and predictors of VTE recurrence have been identified, and effective primary and secondary prophylaxis is available, the occurrence

Full Text available with Trip Pro

2015 Nature reviews. Cardiology

177. Statement on pregnancy and travel

of toxemia, hypertension, or diabetes with any pregnancy / Antécédents de toxémie, d’hypertension artérielle ou de diabète au cours d’une grossesse (passée ou présente) • Primigravida at 35 years of age and older, or 15 years of age and younger / Primigeste de 35 ans et plus ou de 15 ans et moins • History of thromboembolic disease / Antécédents de maladie thrombo- embolique • Pulmonary hypertension / Hypertension artérielle pulmonaire • Severe asthma or other chronic lung disease / Asthme grave ou autre (...) Statement on pregnancy and travel 1 CCDR Canada Communicable Disease Report RMTC Relevé des maladies transmissibles au Canada March 2010 • Volume 36 • ACS-2 March 2010 • Volume 36 • DCC-2 ISSN 1481-8531 Committee to Advise on Tropical Medicine and Travel* † STATEMENT ON PREGNANCY AND TRAVEL This correction note was published in the CCDR Volume 40-8 on April 17, 2014 The “Statement on Pregnancy and Travel” by the Committee to Advise on Tropical Medicine and Travel (CATMAT) † published in March

2010 CPG Infobase

178. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. (PubMed)

and 44 non-academic hospitals in the Netherlands. Women with non-severe hypertensive disorders of pregnancy between 34 and 37 weeks of gestation were randomly allocated to either induction of labour or caesarean section within 24 h (immediate delivery) or a strategy aimed at prolonging pregnancy until 37 weeks of gestation (expectant monitoring). The primary outcomes were a composite of adverse maternal outcomes (thromboembolic disease, pulmonary oedema, eclampsia, HELLP syndrome, placental abruption (...) Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. There is little evidence to guide the management of women with hypertensive disorders in late preterm pregnancy. We investigated the effect of immediate delivery versus expectant monitoring on maternal and neonatal outcomes in such women.We did an open-label, randomised controlled trial, in seven academic hospitals

2015 Lancet

179. Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome

of CYP3A4 and P-gp, such as: 14.a rifampin 14.b carbamazepine 14.c phenytoin 14.d St. John's wort 15. Intend pregnancy or breastfeeding within the next year 16. Have a known allergy to apixaban, rivaroxaban, or edoxaban 17. Have experienced thrombosis while receiving warfarin at a target INR of 2-3 and have been assigned a higher target INR at the discretion of their clinician. 18. Patients with active pathological bleeding. 19. A history of arterial thromboembolism (e.g., stroke, myocardial infarction (...) Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Thrombosis Thromboembolism Antiphospholipid Syndrome Disease Pathologic Processes Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Autoimmune Diseases Immune System Diseases Warfarin Apixaban Anticoagulants Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular

2014 Clinical Trials

180. Prophylaxis of Venous Thromboembolism After Bariatric Surgery

: Rijnstate Hospital Information provided by (Responsible Party): Frits Berends, Rijnstate Hospital Study Details Study Description Go to Brief Summary: This study is a prospective evaluation of the relationship between lean body weight and anti-Xa activity and 5700 International Units (IU) nadroparin 4 hours after subcutaneous administration in morbidly obese patients after bariatric surgery. Condition or disease Intervention/treatment Phase Morbid Obesity Thromboembolism Bypass Complications Drug (...) ) First Posted: November 20, 2014 Last Update Posted: November 20, 2014 Last Verified: November 2014 Keywords provided by Frits Berends, Rijnstate Hospital: Nadroparin Anti-Xa activity Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Obesity, Morbid Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Obesity Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Heparin, Low-Molecular-Weight Dalteparin Nadroparin

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>